Market Closed -
OTC Markets
01:12:59 03/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.059
USD
|
+0.42%
|
|
-7.09%
|
-15.83%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
89.88
|
39.66
|
61.1
|
32.75
|
29.39
|
2.828
|
2.828
|
Enterprise Value (EV)
1 |
89.88
|
39.66
|
61.1
|
32.75
|
29.39
|
2.828
|
2.828
|
P/E ratio
|
-3.83
x
|
-1.27
x
|
-2.49
x
|
-0.61
x
|
-0.73
x
|
0.84
x
|
-0.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
32.6
x
|
38.8
x
|
61.1
x
|
21.3
x
|
9.51
x
|
0.13
x
|
0.37
x
|
EV / Revenue
|
32.6
x
|
38.8
x
|
61.1
x
|
21.3
x
|
9.51
x
|
0.13
x
|
0.37
x
|
EV / EBITDA
|
-
|
-13,79,506
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-36,02,764
x
|
-47,59,320
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,105
|
8,912
|
10,066
|
14,054
|
24,909
|
47,929
|
47,929
|
Reference price
2 |
11.09
|
4.450
|
6.070
|
2.330
|
1.180
|
0.0590
|
0.0590
|
Announcement Date
|
28/03/19
|
08/04/20
|
30/03/21
|
01/04/22
|
22/05/23
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
2.757
|
1.022
|
1
|
1.535
|
3.091
|
21.4
|
7.6
|
EBITDA
|
-
|
-28.75
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.12
|
-29.09
|
-22.4
|
-43.71
|
-29.99
|
5.6
|
-4.3
|
Operating Margin
|
-874.76%
|
-2,846.09%
|
-2,240.1%
|
-2,847.62%
|
-970.33%
|
26.17%
|
-56.58%
|
Earnings before Tax (EBT)
1 |
-22.1
|
-29.68
|
-22.33
|
-43.19
|
-30.37
|
4.3
|
-4.3
|
Net income
1 |
-23.46
|
-29.68
|
-22.33
|
-47.32
|
-30.37
|
4.3
|
-4.3
|
Net margin
|
-851%
|
-2,904.21%
|
-2,233.3%
|
-3,082.74%
|
-982.56%
|
20.09%
|
-56.58%
|
EPS
2 |
-2.894
|
-3.510
|
-2.440
|
-3.850
|
-1.620
|
0.0700
|
-0.0900
|
Free Cash Flow
|
-24.95
|
-8.333
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-904.9%
|
-815.36%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
08/04/20
|
30/03/21
|
01/04/22
|
22/05/23
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
0.033
|
0.515
|
0.57
|
1.187
|
0.292
|
0.399
|
1.213
|
-
|
-
|
0.417
|
0.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.234
|
-21.03
|
-9.969
|
-7.424
|
-7.737
|
-7.412
|
-7.42
|
-
|
-
|
-0.869
|
-1
|
Operating Margin
|
-18,890.91%
|
-4,082.72%
|
-1,748.95%
|
-625.44%
|
-2,649.66%
|
-1,857.64%
|
-611.71%
|
-
|
-
|
-208.39%
|
-333.33%
|
Earnings before Tax (EBT)
1 |
-5.49
|
-21
|
-10.23
|
-7.766
|
-7.979
|
-8.239
|
-10.5
|
-
|
-
|
-0.083
|
-1
|
Net income
1 |
-5.49
|
-24.14
|
-13.37
|
-7.766
|
-7.979
|
-8.239
|
-10.5
|
-
|
12.14
|
-0.083
|
-1
|
Net margin
|
-16,636.36%
|
-4,687.96%
|
-2,345.26%
|
-654.25%
|
-2,732.53%
|
-2,064.91%
|
-865.21%
|
-
|
-
|
-19.9%
|
-333.33%
|
EPS
2 |
-0.4900
|
-1.940
|
-0.9200
|
-0.4400
|
-0.4500
|
-0.4700
|
-0.5000
|
-0.2200
|
0.3300
|
-
|
-0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/21
|
10/11/21
|
01/04/22
|
16/05/22
|
16/08/22
|
21/11/22
|
22/05/23
|
09/06/23
|
14/09/23
|
03/11/23
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-24.9
|
-8.33
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.68
|
0.17
|
0.37
|
-
|
-
|
-
|
-
|
Capex / Sales
|
24.56%
|
17.03%
|
36.7%
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
08/04/20
|
30/03/21
|
01/04/22
|
22/05/23
|
-
|
-
|
Last Close Price
0.059
USD Average target price
2
USD Spread / Average Target +3,289.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.83% | 2.83M | | -1.65% | 103B | | +6.75% | 101B | | +5.71% | 23.07B | | -12.60% | 22.23B | | -9.70% | 18.05B | | -39.98% | 17.18B | | -10.17% | 16.94B | | +6.12% | 14.07B | | +35.47% | 12.35B |
Bio Therapeutic Drugs
|